Logo

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

Share this

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

Shots:

  • Chugai will receive an upfront- development milestone and royalties if the compound is launch as an approved Ab drug. Additionally- Chugai will receive a fee for technology access
  • Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of therapeutic Abs
  • Novo Nordisk will utilize Chugai’s Ab engineering technologies targeting the unmet medical needs and create novel medicines

 ­ Ref: Chugai | Image: Peter Boyle Solicitors

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions